Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Point Therapeutics |
---|---|
Information provided by: | Point Therapeutics |
ClinicalTrials.gov Identifier: | NCT00243204 |
This Phase 3 study will compare the efficacy of talabostat plus docetaxel to docetaxel plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small Cell Lung |
Drug: talabostat mesylate Drug: docetaxel |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
Histologically or cytologically confirmed NSCLC
EXCLUSION CRITERIA:
Clinically significant laboratory abnormalities, specifically:
Study ID Numbers: | PTH-304 |
Study First Received: | October 19, 2005 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00243204 |
Health Authority: | United States: Food and Drug Administration |
Stage IIIb/IV non-small cell lung cancer NSCLC Lung Cancer |
Docetaxel Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |